The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019)

Research output: Contribution to journalArticlepeer-review


  • Tjibbe J Gardenbroek
  • Thomas D Pinkney
  • Saloomeh Sahami
  • Christianne J Buskens
  • Cyriel Y Ponsioen
  • Pieter J Tanis
  • Mark Löwenberg
  • Gijs R van den Brink
  • Ivo A M J Broeders
  • Paul H J M Pullens
  • Tom Seerden
  • Maarten J Boom
  • Rosalie C Mallant-Hent
  • Robert E G J M Pierik
  • Juda Vecht
  • Meindert N Sosef
  • Annick B van Nunen
  • Bart A van Wagensveld
  • Pieter C F Stokkers
  • Michael F Gerhards
  • Jeroen M Jansen
  • Yair Acherman
  • Annekatrien C T M Depla
  • Guido H H Mannaerts
  • Rachel West
  • Shrikanth Pathmakanthan
  • Rebecca Howard
  • Baljit Singh
  • Dmitri Negpodiev
  • Marcel G W Dijkgraaf
  • Geert R A M D'Haens
  • Willem A Bemelman


BACKGROUND: Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness of the intervention compared to standard treatment.

METHODS/DESIGN: These paired phase III multicenter prospective randomised studies will include patients over 18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to randomisation. Patients need to have been medically treated until complete clinical (Mayo score <3) and endoscopic (Mayo score 0 or 1) remission. Patients will then be randomised 1:1 to a control group (maintenance 5-ASA treatment, no appendectomy) or elective laparoscopic appendectomy plus maintenance treatment. The primary outcome measure is the one year cumulative UC relapse rate - defined both clinically and endoscopically as a total Mayo-score ≥5 with endoscopic subscore of 2 or 3. Secondary outcomes that will be assessed include the number of relapses per patient at 12 months, the time to first relapse, health related quality of life and treatment costs, and number of colectomies in each arm.

DISCUSSION: The ACCURE and ACCURE-UK trials will provide evidence on the role and acceptability of appendectomy in the treatment of ulcerative colitis and the effects of appendectomy on the disease course.



Original languageEnglish
Pages (from-to)1-7
JournalJAMA Surgery
Issue number30
Publication statusPublished - 18 Mar 2015


  • Inflammatory bowel disease, Ulcerative colitis, Appendectomy, Surgery , Disease course